iECURE, Inc.
iECURE, Inc.
Categories
Biotechnology
About
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes.
Industry News & Announcements
- iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithi
- iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
- IECURE SECURES CLEARANCE FROM AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION FOR ITS CLINICAL TRIAL APPLICATION FOR THE OTC-HOPE PHASE 1/2 STUDY OF ECUR-
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.